{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:22:15Z","timestamp":1791580935199,"version":"4.3.4"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":594,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1111\/bjh.12736","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T14:45:28Z","timestamp":1389797128000},"page":"102-111","source":"Crossref","is-referenced-by-count":73,"title":["Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10\u00a0002"],"prefix":"10.1111","volume":"165","author":[{"given":"David A.","family":"Rizzieri","sequence":"first","affiliation":[{"name":"Department of Medicine; Duke University Medical Center; Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Alliance Statistical and Data Center; Duke University Medical Center; Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Division of Hematology; The Ohio State University; Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Lozanski","sequence":"additional","affiliation":[{"name":"Department of Pathology; The Ohio State University; Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"Division of Hematology; The Ohio State University; Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayard L.","family":"Powell","sequence":"additional","affiliation":[{"name":"Wake Forest University; Winston Salem NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Shea","sequence":"additional","affiliation":[{"name":"University of North Carolina; Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa","family":"Nattam","sequence":"additional","affiliation":[{"name":"Fort Wayne Medical Oncology & Hematology; Fort Wayne IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoke","sequence":"additional","affiliation":[{"name":"Alliance Statistical and Data Center; Duke University Medical Center; Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Georgetown University Hospital; Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"University of Chicago; Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Alliance for Clinical Trials In Oncology (ACTION)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,15]]},"reference":[{"key":"10.1111\/bjh.12736-BIB0001|bjh12736-cit-0001","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0002|bjh12736-cit-0002","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Annals of Onocology"},{"key":"10.1111\/bjh.12736-BIB0003|bjh12736-cit-0003","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0004|bjh12736-cit-0004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2011.08947.x","article-title":"RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and \u2018unclassifiable\u2019 highly aggressive B-cell lymphoma","volume":"156","author":"Corazzelli","year":"2012","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12736-BIB0005|bjh12736-cit-0005","first-page":"181","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Diebold","year":"2001"},{"key":"10.1111\/bjh.12736-BIB0006|bjh12736-cit-0006","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/bjh.12736-BIB0007|bjh12736-cit-0007","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/annonc\/mdt414","article-title":"A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M\/IVAC regimen for untreated Burkitt's lymphoma","volume":"24","author":"Evens","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1111\/bjh.12736-BIB0008|bjh12736-cit-0008","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.12020","article-title":"Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma","volume":"159","author":"Ferreri","year":"2012","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12736-BIB0009|bjh12736-cit-0009","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2141.1990.tb06368.x","article-title":"MACHO chemotherapy for Stage IV B-cell lymphoma and B-cell acute lymphoblastic leukemia of childhood","volume":"76","author":"Hann","year":"1990","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12736-BIB0010|bjh12736-cit-0010","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0011|bjh12736-cit-0011","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1111\/bjh.12736-BIB0012|bjh12736-cit-0012","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"key":"10.1111\/bjh.12736-BIB0013|bjh12736-cit-0013","first-page":"667a","article-title":"Substantially improved outcome of adult burkitt Non-Hodgkin lymphoma and leukemia patients with rituximab and a short-intensive Chemotherapy; Report of a Large Prospective Multicenter Trial","volume":"120","author":"Hoelzer","year":"2012","journal-title":"Blood ASH Annual Meeting abstracts"},{"key":"10.1111\/bjh.12736-BIB0014|bjh12736-cit-0014","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3324\/haematol.2013.086827","article-title":"High cure rates in Burkitt lymphoma and leukemia: a Northeren Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program","volume":"98","author":"Intermesoli","year":"2013","journal-title":"Haematologica"},{"key":"10.1111\/bjh.12736-BIB0015|bjh12736-cit-0015","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"10.1111\/bjh.12736-BIB0016|bjh12736-cit-0016","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/10428194.2012.715346","article-title":"Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma\/leukemia","volume":"54","author":"Kasamon","year":"2013","journal-title":"Leukemia and Lymphoma"},{"key":"10.1111\/bjh.12736-BIB0017|bjh12736-cit-0017","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1111\/bjh.12736-BIB0018|bjh12736-cit-0018","first-page":"262","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Leoncini","year":"2008"},{"key":"10.1111\/bjh.12736-BIB0019|bjh12736-cit-0019","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non cleaved cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0020|bjh12736-cit-0020","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12185-010-0728-0","article-title":"Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)\/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediated between diffuse large B cell lymphoma and BL","volume":"92","author":"Maruyama","year":"2010","journal-title":"International Journal of Hematology"},{"key":"10.1111\/bjh.12736-BIB0021|bjh12736-cit-0021","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.1991.9.6.941","article-title":"Effective treatment of small non-cleaved cell lymphoma with high-intensity brief-duration chemotherapy","volume":"9","author":"McMaster","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0022|bjh12736-cit-0022","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An International evaluation of CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of the United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1111\/bjh.12736-BIB0023|bjh12736-cit-0023","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"10.1111\/bjh.12736-BIB0024|bjh12736-cit-0024","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase 2 window study on rituximab in newly diagnosed pediatric mature B cell NHL lymphoma and Burkitt Leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0025|bjh12736-cit-0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2141.2010.08447.x","article-title":"Rituximab in combination with CODOX-M\/IVAC: a retrospective analysis of 23 cases of non-HIV related B cell Non-Hodgkin Lymphoma with proliferation index >95%","volume":"152","author":"Mohamedbhai","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12736-BIB0026|bjh12736-cit-0026","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.1986.4.12.1732","article-title":"Results of treatment of advanced-stage Burkitt lymphoma and B-cell acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine","volume":"4","author":"Murphy","year":"1986","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0027|bjh12736-cit-0027","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1111\/bjh.12736-BIB0028|bjh12736-cit-0028","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1200\/JCO.2009.22.2547","article-title":"Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia","volume":"27","author":"Rao","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0029|bjh12736-cit-0029","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","article-title":"Intensive chemotherapy with and without cranial radiation for Burkitt Leukemia and Lymphoma final results of cancer and Leukemia Group B Study 9251","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"key":"10.1111\/bjh.12736-BIB0030|bjh12736-cit-0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.1991.9.1.133","article-title":"HiCOM: a two-month intensive chemotherapy regimen for children with Stage III and IV Burkitt lymphoma and B-cell acute lymphoblastic leukemia","volume":"9","author":"Schwenn","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12736-BIB0031|bjh12736-cit-0031","doi-asserted-by":"crossref","first-page":"939","DOI":"10.7326\/0003-4819-109-12-939","article-title":"The non-Hodgkin's lymphoma Pathologic classification project: long-term follow up of 1,153 patients with non-Hodgkin's lymphoma","volume":"109","author":"Simon","year":"1988","journal-title":"Annals of Internal Medicine"},{"key":"10.1111\/bjh.12736-BIB0032|bjh12736-cit-0032","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/bjh.12736-BIB0033|bjh12736-cit-0033","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with Hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-Like lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/bjh.12736-BIB0034|bjh12736-cit-0034","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"Journal of Clinical Oncology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12736","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjh.12736\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T08:41:56Z","timestamp":1625388116000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,15]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1111\/bjh.12736","relation":{},"ISSN":["0007-1048"],"issn-type":[{"value":"0007-1048","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,15]]}}}